Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21

This publication has 31 references indexed in Scilit:

• Rhoptry-Associated Protein 1-Binding Monoclonal Antibody Raised against a Heterologous Peptide Sequence InhibitsPlasmodium falciparumGrowth In Vitro
  Infection and Immunity, 2001
• The SPf66 Malaria Vaccine: What is the Evidence for Efficacy?
  Parasitology Today, 1998
• QS-21: a water-soluble triterpene glycoside adjuvant
  Expert Opinion on Investigational Drugs, 1998
• SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission
  Vaccine, 1994
• T-Cell Control of Immunity to the Asexual Blood Stages of the Malaria Parasite
  Critical Reviews in Immunology, 1994
• Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia
  The Lancet, 1993
• The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity
  Vaccine, 1992
• Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria
  Clinical and Experimental Immunology, 1991
• A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria
  Nature, 1988
• Induction of protective immunity against experimental infection with malaria using synthetic peptides
  Nature, 1987